CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 185 enrolled
Drug / intervention
No Interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02383576
NCT02383576N/ACompleted

Retrospective Data Collection: Post Study Treatment Anticancer Therapy From All Randomized Patients Involved in IMELDA MO22223

Hoffmann-La Roche·observational·Posted Mar 9, 2015·Updated Apr 13, 2018

In Brief

An observational study evaluating No Intervention for Breast Cancer. Completed, enrolled 185 participants across 32 sites in 6 countries.

Detailed Summary

This study aims to understand better the effective results from the IMELDA MO22223 P-trial (NCT00929240) and see if the anti-cancer therapies given during its follow-up time after study treatments were terminated possibly had an effect on efficacy results.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesBrazil, France, India, Italy, Spain, Turkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 9, 2015
Enrollment StartApr 30, 2015
Primary CompletionJan 22, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.3 years ago

Interventions

No Interventionother

No intervention administered in this study.